Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses

Abstract

Purpose of review There is growing consensus that eliciting CD8+ T cells in addition to antibodies may be required for an effective HIV vaccine for both prevention and cure. Here, we review key qualities of vaccine-elicited CD8+ T cells as well as major CD8+ T cell-based delivery platforms used in recent HIV vaccine clinical trials. Recent findings Much progress has been made in improving HIV immunogen design and delivery platforms to optimize CD8+ T cell responses. With regards to viral vectors, recent trials have tested newer chimp and human adenovirus vectors as well as a CMV vector. DNA vaccine immunogenicity has been increased by delivering the vaccines by electroporation and together with adjuvants as well as administering them as part of a heterologous regimen. In preclinical models, self-amplifying RNA vaccines can generate durable tissue-based CD8+ T cells. While it may be beneficial for HIV vaccines to recapitulate the functional and phenotypic features of HIV-specific CD8+ T cells isolated from elite controllers, most of these features are not routinely measured in HIV vaccine clinical trials. Summary Identifying a vaccine capable of generating durable T cell responses that target mutationally vulnerable epitopes and that can rapidly intercept infecting or rebounding virus remains a challenge for HIV. Comprehensive assessment of HIV vaccine-elicited CD8+ T cells, as well as comparisons between different vaccine platforms, will be critical to advance our understanding of how to design better CD8+ T cell-based vaccines for HIV.

Preference for novel biomedical HIV pre-exposure prophylaxis methods among adolescent girls and young women in Kampala, Uganda: a mixed methods study

“…Longer duration of protection may therefore be a game changer for future HIV vaccine(s). Newer vaccine strategies focused on eliciting broadly neutralizing antibodies ( 42 ) and functional killer T-cells ( 43 ), are being employed to develop HIV vaccines that offer broad, durable responses that would ensure a profile that offers benefits over what has been achieved with long-acting PrEP products. After the rapid vaccine development during COVID, delivery technologies such as viral vectors and mRNA technology are being employed to accelerate the development timeline for HIV vaccines.…”